An Open-label Phase II Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 17 Jun 2020 Planned number of patients changed from 400 to 500.
- 17 Jun 2020 Planned End Date changed from 1 Dec 2023 to 1 Dec 2033.
- 17 Jun 2020 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2033.